신경 기기 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Neurology Devices Market was valued at USD 14.3 billion in 2024 and is estimated to grow at a CAGR of 7.2% to reach USD 28.3 billion by 2034, fueled by a combination of technological innovation, rising rates of neurological conditions, increased healthcare spending, and improved access to medical services. Developments in AI-powered remote monitoring and brain-computer interface systems have significantly improved patient care outcomes. In addition, emerging minimally invasive neurotechnologies-such as portable EEG monitors and enhanced stimulation systems-are transforming neurological treatment and diagnosis. These advances have made it possible to deliver more precise, safer, and efficient therapeutic interventions, contributing to the overall expansion of the neurology devices sector. Neurology devices include implantable tools, surgical instruments, and diagnostic technologies used to manage conditions affecting the nervous system, such as the brain, spine, and peripheral nerves.

Neurology devices include implantable tools, surgical instruments, and diagnostic technologies used to manage conditions affecting the nervous system, such as the brain, spine, and peripheral nerves. These devices are designed to aid in the detection, monitoring, treatment, and rehabilitation of neurological disorders, including epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis, brain tumors, and traumatic brain injuries. They serve a critical role across a range of clinical settings, from routine neurological assessments to complex neurosurgical procedures. Diagnostic tools such as EEG systems and neuroimaging technologies help in the early and accurate identification of neurological conditions, while implantable devices like neurostimulators offer long-term therapeutic benefits for patients suffering from chronic and progressive diseases.

Among the main categories, the neurostimulation devices segment generated USD 7 billion in 2024. These include systems like spinal cord stimulators and vagus nerve stimulators, designed to address movement disorders, chronic pain, psychiatric issues, and epilepsy. Newer models, such as closed-loop systems, MRI-compatible implants, and miniaturized solutions, have improved patient outcomes and broadened therapeutic applications, reinforcing growth in this segment.

By end use, hospitals led the market in 2024 with a dominant share of 56.1%, driven by their comprehensive infrastructure and ability to handle complex neurological cases. Hospitals conduct a majority of diagnostic and therapeutic procedures, making them key hubs for the adoption of neuroimaging and neuromodulation systems. Their role in managing emergency neurological events such as seizures, strokes, and traumatic injuries ensures constant demand for cutting-edge equipment.

United States Neurology Devices Market was valued at USD 5.2 billion in 2024, supported by increasing neurological disease prevalence, robust clinical research infrastructure, and substantial government funding. Major federal initiatives and research grants continue to back advancements in neuroprosthetics and brain-computer interface systems. A growing elderly population and a shortage of specialized neurology professionals are also pushing greater reliance on advanced devices to meet the rising demand for care.

Key players actively shaping The Neurology Devices Industry landscape include Synchron, B BRAUN, LivaNova, NeuroPace, ZYLOX TONBRIDGE, Abbott Laboratories, MicroTransponder, KARL STROZ, Medtronic, stryker, Bioness, nevro, Boston Scientific, Enterra Medical, and Paradromics. To strengthen their position in the neurology devices market, leading companies are focusing on research-driven product innovation and the development of AI-integrated systems. These firms are expanding their portfolios with minimally invasive devices and patient-specific solutions that enhance safety and precision. Strategic partnerships, regulatory approvals, and increased investments in neurotechnology R&D are also central to their approach. Businesses are refining device compatibility with imaging systems and pursuing compact, portable formats for broader clinical use. Additionally, major players are scaling up manufacturing capabilities and entering into global collaborations to secure contracts, boost geographic presence, and align with healthcare systems aiming for smarter neurological care delivery.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of neurological disorders
    • 3.2.1.2 Growing adoption of minimally invasive procedure
    • 3.2.1.3 Technological advancements
    • 3.2.1.4 Increased funding and investments
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of devices and procedures
    • 3.2.2.2 Risk of device failure and complications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Technology landscape
• 3.6 Trump administration tariffs
  • 3.6.1 Impact on trade
    • 3.6.1.1 Trade volume disruptions
    • 3.6.1.2 Retaliatory measures
  • 3.6.2 Impact on the Industry
    • 3.6.2.1 Supply-side impact (raw materials)
      • 3.6.2.1.1 Price volatility in key materials
      • 3.6.2.1.2 Supply chain restructuring
      • 3.6.2.1.3 Production cost implications
    • 3.6.2.2 Demand-side impact (selling price)
      • 3.6.2.2.1 Price transmission to end markets
      • 3.6.2.2.2 Market share dynamics
      • 3.6.2.2.3 Consumer response patterns
  • 3.6.3 Key companies impacted
  • 3.6.4 Strategic industry responses
    • 3.6.4.1 Supply chain reconfiguration
    • 3.6.4.2 Pricing and product strategies
    • 3.6.4.3 Policy engagement
  • 3.6.5 Outlook and future considerations
• 3.7 Reimbursement scenario
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Gap analysis
• 3.11 Future market trends
• 3.12 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Device, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Neurostimulation devices
  • 5.2.1 Spinal cord stimulators
  • 5.2.2 Deep brain stimulators
  • 5.2.3 Vagus nerve stimulators
  • 5.2.4 Sacral nerve stimulators
  • 5.2.5 Gastric electrical stimulators
• 5.3 Neurosurgical devices
  • 5.3.1 Stereotactic systems
  • 5.3.2 Neuroendoscopes
  • 5.3.3 Ultrasonic aspirators
  • 5.3.4 Aneurysm clips
• 5.4 Interventional neurology devices
  • 5.4.1 Aneurysm coiling and embolisation
    • 5.4.1.1 Embolic coils
    • 5.4.1.2 Flow diversion devices
    • 5.4.1.3 Liquid embolic reagents
  • 5.4.2 Neurothromobectomy
    • 5.4.2.1 Clot retrievers
    • 5.4.2.2 Suction aspiration devices
    • 5.4.2.3 Snare devices
  • 5.4.3 Neurovascular catheters
    • 5.4.3.1 Micro catheters
    • 5.4.3.2 Micro guidewires
  • 5.4.4 Cerebral balloon angioplasty and stents
    • 5.4.4.1 Carotid artery stents
    • 5.4.4.2 Filter devices
    • 5.4.4.3 Balloon occlusion devices
  • 5.4.5 Csf management devices
    • 5.4.5.1 Cerebral shunts
    • 5.4.5.2 Cerebral external drainage
• 5.5 Brain-computer interface devices
  • 5.5.1 Non-invasive BCI
  • 5.5.2 Partially invasive BCI
  • 5.5.3 Fully invasive BCI
• 5.6 Other devices

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Chronic pain management
• 6.3 Parkinson’s disease
• 6.4 Epilepsy
• 6.5 Stroke management and recovery
• 6.6 Alzheimer
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 B BRAUN
• 9.3 Bioness
• 9.4 Boston Scietific
• 9.5 enterra medical
• 9.6 KARL STROZ
• 9.7 LivaNova
• 9.8 Medtronic
• 9.9 MicroTransponder
• 9.10 NeuroPace
• 9.11 nevro
• 9.12 Paradromics
• 9.13 stryker
• 9.14 synchron
• 9.15 ZYLOX TONBRIDGE